Curated news and analysis on clinical trials, drug approvals, and medical research.
Sac-TMT met the PFS endpoint in the phase 3 OptiTROP-Breast03 trial for advanced TNBC. Research links HER2-low to poorer immunotherapy response, introduces the TmS biomarker, and identifies drug-resistant cell states.
NHMRC Tracker newsletters cover the new Research Translation Strategy 2026–2030, a revised generative AI policy, RRR Capacity Building grants, and consultations on drinking water and clinical guidelines.
New research reveals how TB bacteria resist drugs via PE/PPE proteins and evade immune defenses by stiffening cell membranes. TB remains the leading infectious killer, with 1.23 million deaths in 2024.
A study in JAMA Open finds that anti-kickback penalties paid by pharma companies amounted to just 2.2% of U.S. revenue from involved drugs. Pfizer recently disclosed $60,000 in lobbying on drug pricing and vaccine issues. Researchers say settlements act as a cost of doing business.
The Agency for Healthcare Research and Quality has cut off continuing funding for at least 73 projects, totaling over $102 million in committed funds. HHS says the move serves the federal government's best interest, but researchers warn that mid-stream grant freezes waste already-spent money and threaten the training of future health-care scientists.
Global pharma sales are projected to exceed $1.2 trillion in 2026. Merck yields 2.8% with 15 straight dividend increases, while J&J's pipeline gained FDA approvals. Major pharma yields reach 6.6%.
Cornerstone Robotics will present at the 2nd Global Health Summit in August 2026, where its CEO will deliver a keynote on the evolution of surgical robotics. The company's Sentire surgical system has secured regulatory approvals in China, the EU, and Singapore, and is now used in hospitals across Asia-Pacific and Europe.
Semiconductor stocks surged as Intel, AMD, and POET hit fresh highs on AI infrastructure demand, while SemiLEDS jumped 17.96% after a Q3 turnaround. Intel posted stronger-than-expected Q1 earnings and upbeat Q2 guidance.
Amgen detailed its T-cell engager and precision therapy strategy at Citi's 2026 summit. GT Biopharma, Onco-Innovations, Oncotelic, and Samsung Biologics also advanced AI and organoid platforms in drug development.
Law enforcement in three states arrested 11 people in separate drug investigations, seizing cocaine, methamphetamine, fentanyl, LSD, firearms and body armor. The arrests followed anonymous tips, a police pursuit, a traffic stop and search warrants.
A 64-year-old Australian man was diagnosed with stage 3 breast cancer after his wife noticed bloodstains on his shirt, a case doctors say highlights that men can and do get the disease. Meanwhile, advances in precision medicine now allow breast cancer treatment to be tailored to each tumour’s biology and the patient’s overall health.
STAR-221 found domvanalimab plus chemotherapy did not improve OS vs nivolumab in HER2-negative gastric cancer. Pembrolizumab plus high-dose IL-2 achieved 73% ORR in advanced RCC. OPTIM is testing post-nivolumab strategies in head and neck cancer.
Arbutus and Genevant filed three new lawsuits against Pfizer and BioNTech over mRNA vaccine lipid nanoparticle patents, shortly after receiving a $178 million payment from Moderna. Sanofi also launched two separate patent suits against Pfizer and Moderna. A Delaware court previously narrowed Moderna's defenses in a related case.
Genmab's Phase III EPCORE DLBCL-4 trial met its primary endpoint: Epkinly plus lenalidomide improved PFS in R/R DLBCL. At EHA 2026, epcoritamab monotherapy and combinations showed high response rates in elderly newly diagnosed DLBCL.
The FDA has upgraded a peanut butter recall to Class II after blue plastic fragments were found in a production filter. More than 22,000 single-serve packs from Ventura Foods were distributed to 40 states under various private-label brands. Consumers are advised to check labels and return or discard affected products.
Axpaxli (OTX-TKI) met its primary endpoint in the SOL-1 Phase 3 trial, demonstrating superiority over aflibercept in preserving visual acuity in wet AMD patients at week 36. A single injection of the intravitreal hydrogel led to higher rescue-free rates and better fluid control, supporting potential for reduced treatment burden. Ocular Therapeutix plans to submit a New Drug Application to the FDA.
Lidocaine patches cut opioid use after radiofrequency ablation for hepatocellular carcinoma; a protocol tests liposomal bupivacaine for mastectomy; a pipeline report profiles 40+ companies.
A cross-sectional study shows that type 2 diabetes and body mass index independently worsen arterial stiffness, with BMI having a greater impact. No synergy was found between the two risk factors.
Three infant botulism cases prompted Nara Organics to recall its organic formula. Federal records also show formula makers sent no death reports to the FDA in 26 years, and separate tests found PFAS and patulin.
England will screen all newborns for SMA after Jesy Nelson's campaign. A real-world study found Zolgensma helped children with SMA achieve motor milestones, with newborn screening leading to earlier gains.
